Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial

From the report

Nature Medicine, Published online: 14 October 2026; doi:10.1038/s41591-026-04671-5In the randomized multicenter phase 2 ZZ-FIRST trial, patients with high-volume metastatic hormone-sensitive prostate cancer treated with poly(ADP-ribose) polymerase inhibitor talazoparib combined with androgen receptor inhibitor enzalutamide had an improved prostate-specific antigen response compared with enzalutamide alone, and spatial transcriptomic analyses of paired biopsies linked AR inhibition-induced suppression…